NYSE:DGX - Quest Diagnostics Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $150.33
  • Forecasted Upside: 12.54 %
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 7 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$133.58
▼ -2.43 (-1.79%)

This chart shows the closing price for DGX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Quest Diagnostics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DGX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DGX

Analyst Price Target is $150.33
▲ +12.54% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Quest Diagnostics in the last 3 months. The average price target is $150.33, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 12.54% upside from the last price of $133.58.

This chart shows the closing price for DGX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 10 investment analysts is to hold stock in Quest Diagnostics. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 14 hold ratings
  • 0 sell ratings
1/11/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 13 hold ratings
  • 0 sell ratings
4/11/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 8 hold ratings
  • 0 sell ratings
7/10/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 7 hold ratings
  • 0 sell ratings
10/8/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 8 hold ratings
  • 0 sell ratings
1/6/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 7 hold ratings
  • 0 sell ratings
4/6/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 7 hold ratings
  • 0 sell ratings
6/5/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 7 hold ratings
  • 0 sell ratings
7/5/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 7 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/25/2022Wells Fargo & CompanyBoost Price TargetEqual Weight$145.00 ➝ $150.00Medium
4/24/2022UBS GroupBoost Price Target$139.00 ➝ $150.00Low
4/22/2022Bank of AmericaLower Price TargetBuy$166.00 ➝ $163.00High
4/4/2022CitigroupDowngradeBuy ➝ Neutral$175.00 ➝ $140.00Low
2/23/2022UBS GroupDowngradeBuy ➝ Neutral$160.00 ➝ $139.00Medium
2/14/2022Morgan StanleyLower Price TargetEqual Weight$159.00 ➝ $145.00High
2/4/2022Wells Fargo & CompanyLower Price TargetEqual Weight$160.00 ➝ $145.00Medium
2/4/2022Robert W. BairdLower Price Target$162.00 ➝ $146.00Medium
2/2/2022Jefferies Financial GroupDowngradeBuy ➝ Hold$135.00Medium
1/28/2022Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold$190.00 ➝ $129.00Medium
1/19/2022Truist FinancialLower Price Target$170.00 ➝ $160.00Low
1/13/2022Robert W. BairdLower Price Target$173.00 ➝ $162.00High
1/10/2022Deutsche Bank AktiengesellschaftBoost Price Target$160.00 ➝ $190.00High
1/5/2022Truist FinancialBoost Price Target$150.00 ➝ $170.00High
12/17/2021Morgan StanleyLower Price TargetEqual Weight$165.00 ➝ $159.00Low
12/14/2021Wells Fargo & CompanyBoost Price TargetEqual Weight ➝ Equal Weight$150.00 ➝ $160.00Medium
12/13/2021KeyCorpBoost Price TargetOverweight$168.00 ➝ $170.00High
10/26/2021Wells Fargo & CompanyBoost Price TargetEqual Weight$140.00 ➝ $150.00Low
10/22/2021Deutsche Bank AktiengesellschaftBoost Price TargetBuy$150.00 ➝ $160.00Low
9/10/2021CitigroupBoost Price TargetBuy$158.00 ➝ $181.00High
9/1/2021KeyCorpBoost Price TargetIn-Line ➝ Overweight$144.00 ➝ $168.00Low
8/31/2021Morgan StanleyBoost Price TargetEqual Weight$136.00 ➝ $165.00High
8/19/2021MizuhoBoost Price TargetBuy$158.00 ➝ $166.00High
8/13/2021Credit Suisse GroupBoost Price TargetNeutral$135.00 ➝ $150.00Low
7/23/2021Jefferies Financial GroupInitiated CoverageBuy$160.00Low
5/12/2021MizuhoBoost Price TargetBuy$149.00 ➝ $158.00Medium
5/4/2021UBS GroupUpgradeNeutral ➝ Buy$135.00 ➝ $158.00High
3/18/2021Robert W. BairdReiterated RatingOutperform ➝ Neutral$137.00Low
3/12/2021Morgan StanleyBoost Price TargetEqual Weight$130.00 ➝ $136.00Low
3/12/2021Robert W. BairdDowngradeOutperform ➝ Neutral$137.00Low
1/29/2021CitigroupBoost Price Target$151.00 ➝ $158.00Low
12/17/2020Morgan StanleyDowngradeOverweight ➝ Equal WeightLow
10/26/2020MizuhoBoost Price TargetBuy$144.00 ➝ $149.00Medium
10/23/2020Wells Fargo & CompanyReiterated RatingHoldLow
10/21/2020ArgusUpgradeHold ➝ Buy$135.00Medium
10/14/2020Jefferies Financial GroupBoost Price TargetBuy$125.00 ➝ $134.00Medium
7/24/2020Deutsche Bank AktiengesellschaftBoost Price TargetTop Pick ➝ Buy$140.00 ➝ $150.00Medium
7/24/2020MizuhoBoost Price TargetBuy$114.00 ➝ $144.00Medium
7/24/2020CitigroupBoost Price TargetBuy$130.00 ➝ $151.00Medium
7/14/2020Credit Suisse GroupBoost Price TargetNeutral$126.00 ➝ $128.00High
7/14/2020Bank of AmericaUpgradeNeutral ➝ Buy$142.00High
6/9/2020Wells Fargo & CompanyUpgradeUnderweight ➝ Equal Weight$90.00 ➝ $120.00Low
6/1/2020Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy$140.00High
5/21/2020SunTrust BanksBoost Price TargetHold$110.00 ➝ $130.00Low
5/20/2020Morgan StanleyBoost Price TargetOverweight$139.00 ➝ $146.00Medium
5/5/2020UBS GroupBoost Price TargetNeutral$106.00 ➝ $111.00Low
4/30/2020Bank of AmericaBoost Price TargetNeutral$105.00 ➝ $120.00Low
4/28/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight$95.00 ➝ $139.00High
4/27/2020Wolfe ResearchUpgradeUnderperform ➝ Market Perform$116.00Medium
4/27/2020CitigroupUpgradeNeutral ➝ Buy$113.00 ➝ $130.00High
4/24/2020Credit Suisse GroupReiterated RatingHold$100.00Low
4/23/2020JPMorgan Chase & Co.Boost Price TargetNeutral$87.00 ➝ $111.00Medium
4/23/2020SunTrust BanksBoost Price TargetHold$100.00 ➝ $110.00Low
4/23/2020BarclaysBoost Price TargetEqual Weight$93.00 ➝ $99.00Low
4/23/2020Wells Fargo & CompanyBoost Price TargetUnderweight$80.00 ➝ $90.00Low
4/22/2020CfraDowngradeStrong-Buy ➝ Hold$140.00 ➝ $106.00Medium
4/16/2020MizuhoLower Price TargetBuy$110.00 ➝ $106.00Medium
4/13/2020SunTrust BanksLower Price TargetHold$115.00 ➝ $100.00Low
4/2/2020JPMorgan Chase & Co.Lower Price TargetNeutral$99.00 ➝ $87.00Low
3/30/2020Wells Fargo & CompanyLower Price TargetUnderweight$100.00 ➝ $80.00Low
3/27/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$95.00High
3/26/2020BarclaysLower Price TargetEqual Weight$106.00 ➝ $93.00Low
3/5/2020CfraUpgradeHold ➝ Strong-Buy$116.00 ➝ $140.00Low
2/10/2020MizuhoBoost Price TargetBuy$116.00 ➝ $122.00Low
2/3/2020CitigroupBoost Price TargetNeutral$110.00 ➝ $113.00Low
1/31/2020Bank of AmericaBoost Price TargetNeutral$110.00 ➝ $116.00Low
1/31/2020Robert W. BairdBoost Price TargetOutperform$113.00 ➝ $118.00Low
1/30/2020Piper SandlerBoost Price TargetHold$102.00 ➝ $107.00Low
1/7/2020Wells Fargo & CompanyInitiated CoverageUnderweight$100.00Low
1/7/2020BarclaysDowngradeOverweight ➝ Equal Weight$106.00Medium
1/3/2020Bank of AmericaDowngradeNeutral ➝ UnderperformLow
12/19/2019Bank of AmericaUpgradeUnderperform ➝ Neutral$94.00 ➝ $110.00Low
10/21/2019UBS GroupLower Price TargetNeutral$103.00 ➝ $102.00Low
8/23/2019Morgan StanleyBoost Price TargetOverweight$111.00 ➝ $121.00High
8/8/2019Evercore ISIReiterated RatingBuy$108.00Low
7/24/2019JPMorgan Chase & Co.Boost Price TargetNeutral$100.00 ➝ $111.00Low
7/24/2019Morgan StanleyBoost Price TargetOverweight$104.00 ➝ $111.00Low
7/24/2019Credit Suisse GroupBoost Price TargetNeutral$99.00 ➝ $105.00Low
7/15/2019The Goldman Sachs GroupDowngradeNeutral ➝ Sell$90.00 ➝ $85.00High
5/20/2019MizuhoSet Price TargetBuy$110.00Low
4/25/2019Morgan StanleyBoost Price TargetOverweight ➝ Overweight$98.00 ➝ $104.00Low
4/24/2019UBS GroupBoost Price TargetNeutral$91.00 ➝ $99.00Low
4/24/2019CitigroupBoost Price TargetNeutral$93.00 ➝ $102.00Medium
4/2/2019Wolfe ResearchInitiated CoverageUnderperformLow
4/2/2019Jefferies Financial GroupUpgradeHold ➝ Buy$93.00 ➝ $107.00Low
3/18/2019Credit Suisse GroupDowngradeOutperform ➝ Neutral$101.00 ➝ $91.00Low
2/19/2019Credit Suisse GroupLower Price TargetOutperform ➝ Outperform$103.00 ➝ $101.00Low
2/15/2019MizuhoSet Price TargetBuy$106.00Low
2/15/2019UBS GroupSet Price TargetHold$91.00Low
2/15/2019BarclaysReiterated RatingBuy$114.00Low
2/14/2019Piper Jaffray CompaniesLower Price TargetNeutral$110.00 ➝ $100.00High
1/31/2019ArgusDowngradeBuy ➝ HoldMedium
1/17/2019UBS GroupInitiated CoverageNeutral ➝ Neutral$90.00Low
1/3/2019Bank of AmericaDowngradeNeutral ➝ UnderperformMedium
12/20/2018Morgan StanleySet Price TargetBuy$101.00Medium
12/9/2018The Goldman Sachs GroupLower Price TargetBuy ➝ Neutral$110.00 ➝ $90.00Low
12/3/2018SunTrust BanksLower Price TargetHold ➝ Positive$96.00Medium
12/3/2018Bank of AmericaDowngradeBuy ➝ NeutralMedium
12/2/2018Credit Suisse GroupReiterated RatingBuy$121.00Medium
11/30/2018BarclaysLower Price TargetOverweight ➝ Overweight$125.00 ➝ $117.00Low
11/30/2018Craig HallumReiterated RatingHold$94.00Medium
11/30/2018Credit Suisse GroupLower Price TargetOutperform ➝ Outperform$121.00 ➝ $103.00Medium
11/30/2018Morgan StanleyLower Price TargetOverweight ➝ Overweight$120.00 ➝ $107.00Medium
11/30/2018The Goldman Sachs GroupDowngradeBuy ➝ Neutral$110.00 ➝ $90.00Low
11/20/2018MizuhoSet Price TargetBuy$108.00Medium
10/24/2018ArgusSet Price TargetBuy$106.00Low
10/24/2018BarclaysLower Price TargetOverweight ➝ Overweight$130.00 ➝ $125.00Medium
10/24/2018Credit Suisse GroupLower Price TargetOutperform ➝ Outperform$128.00 ➝ $121.00High
10/24/2018CitigroupLower Price TargetNeutral ➝ Neutral$112.00 ➝ $104.00High
10/24/2018JPMorgan Chase & Co.Lower Price TargetNeutral ➝ Neutral$114.00 ➝ $107.00High
10/23/2018William BlairReiterated RatingOutperformLow
10/19/2018Bank of AmericaInitiated CoverageBuy ➝ BuyLow
9/24/2018Credit Suisse GroupBoost Price TargetOutperform$121.00 ➝ $128.00Low
9/14/2018ArgusSet Price TargetBuy$116.00 ➝ $120.00Low
7/10/2018Evercore ISIUpgradeIn-Line ➝ Outperform$103.00High
6/27/2018Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold$108.00High
6/25/2018BarclaysUpgradeEqual Weight ➝ Overweight$120.00 ➝ $130.00High
6/8/2018William BlairUpgradeMarket Perform ➝ OutperformHigh
5/29/2018Morgan StanleyUpgradeEqual Weight ➝ Overweight$120.00Low
5/28/2018BarclaysReiterated RatingHold$120.00Low
5/25/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$118.00 ➝ $121.00Low
5/25/2018MizuhoReiterated RatingBuyHigh
5/1/2018Robert W. BairdUpgradeNeutral ➝ Outperform$115.00Medium
3/14/2018Morgan StanleyUpgradeUnderweight ➝ Equal Weight$103.00Low
3/7/2018ArgusUpgradeHold ➝ Buy$104.14 ➝ $116.00Low
2/13/2018Credit Suisse GroupUpgradeNeutral ➝ Outperform$107.00Medium
2/2/2018Credit Suisse GroupInitiated CoverageNeutral ➝ Neutral$107.00Low
2/1/2018Piper Jaffray CompaniesReiterated RatingHold$110.00Low
1/29/2018The Goldman Sachs GroupInitiated CoverageBuy ➝ Buy$117.00Medium
1/24/2018MizuhoSet Price TargetBuy$113.00Low
1/4/2018Evercore ISIInitiated CoverageIn ➝ In-Line$103.00Low
11/25/2017Jefferies Financial GroupSet Price TargetHold$98.00Low
10/27/2017KeyCorpReiterated RatingHoldN/A
10/20/2017Wells Fargo & CompanyLower Price TargetMarket Perform$88.00 ➝ $86.00N/A
10/20/2017CitigroupLower Price TargetNeutral$110.00 ➝ $98.00N/A
10/19/2017MizuhoSet Price TargetBuy ➝ Buy$122.00 ➝ $103.00N/A
10/17/2017Craig HallumReiterated RatingHold$110.00 ➝ $100.00N/A
10/15/2017SunTrust BanksSet Price TargetHold$105.00N/A
10/12/2017Wells Fargo & CompanyInitiated CoverageUnderperform ➝ Market Perform$88.00N/A
10/10/2017The Goldman Sachs GroupDowngradeConviction-Buy ➝ Buy$121.00 ➝ $113.00N/A
9/28/2017Credit Suisse GroupLower Price TargetNeutral$110.00 ➝ $99.00Low
9/25/2017Raymond JamesReiterated RatingOutperform ➝ Market PerformHigh
8/10/2017Morgan StanleyBoost Price TargetUnderweight$87.00 ➝ $92.00Low
7/25/2017Bank of AmericaUpgradeNeutral ➝ Buy$111.00 ➝ $118.00Medium
7/25/2017Piper Jaffray CompaniesBoost Price TargetNeutral$107.00High
7/19/2017BarclaysReiterated RatingHold$110.00Low
7/13/2017Credit Suisse GroupReiterated RatingNeutral$83.00 ➝ $110.00Low
7/6/2017UBS GroupBoost Price TargetBuy$115.00 ➝ $123.00N/A
(Data available from 7/5/2017 forward)

News Sentiment Rating

0.70 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 6 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
12/7/2021
  • 8 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/6/2022
  • 13 very positive mentions
  • 28 positive mentions
  • 4 negative mentions
  • 2 very negative mentions
2/5/2022
  • 8 very positive mentions
  • 28 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
3/7/2022
  • 8 very positive mentions
  • 18 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
4/6/2022
  • 7 very positive mentions
  • 28 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/6/2022
  • 7 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/5/2022
  • 11 very positive mentions
  • 14 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
7/5/2022

Current Sentiment

  • 11 very positive mentions
  • 14 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Quest Diagnostics logo
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Read More

Today's Range

Now: $133.58
Low: $131.35
High: $134.72

50 Day Range

MA: $136.18
Low: $127.07
High: $145.39

52 Week Range

Now: $133.58
Low: $125.33
High: $174.16

Volume

745,273 shs

Average Volume

1,165,885 shs

Market Capitalization

$15.68 billion

P/E Ratio

8.89

Dividend Yield

1.93%

Beta

1.03

Frequently Asked Questions

What sell-side analysts currently cover shares of Quest Diagnostics?

The following sell-side analysts have issued research reports on Quest Diagnostics in the last twelve months: Bank of America Co., Citigroup Inc., Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, Jefferies Financial Group Inc., KeyCorp, Mizuho, Morgan Stanley, Robert W. Baird, StockNews.com, Truist Financial Co., UBS Group AG, and Wells Fargo & Company.
View the latest analyst ratings for DGX.

What is the current price target for Quest Diagnostics?

0 Wall Street analysts have set twelve-month price targets for Quest Diagnostics in the last year. Their average twelve-month price target is $150.33, suggesting a possible upside of 12.5%.
View the latest price targets for DGX.

What is the current consensus analyst rating for Quest Diagnostics?

Quest Diagnostics currently has 7 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in DGX, but not buy more shares or sell existing shares.
View the latest ratings for DGX.

What other companies compete with Quest Diagnostics?

How do I contact Quest Diagnostics' investor relations team?

Quest Diagnostics' physical mailing address is 500 PLAZA DRIVE, SECAUCUS NJ, 07094. The medical research company's listed phone number is (973) 520-2700 and its investor relations email address is [email protected] The official website for Quest Diagnostics is www.questdiagnostics.com. Learn More about contacing Quest Diagnostics investor relations.